Two months after Merck acquired Seattle-based biotech Immune Design for $300 million, the president of Merck Research Laboratories, Roger Perlmutter,… Read More
Seattle-based startup Navigating Cancer has raised $12 million for its digital platform that lets cancer doctors interact with their patients.… Read More
Seattle Genetics on Thursday reported higher-than-expected losses for the fourth quarter, sending shares down 8 percent in after-hours trading. Quarterly… Read More
Adaptive Biotechnologies has signed a $300 million collaborative licensing agreement with Genentech to develop highly personalized cancer therapies. In addition… Read More
Seattle-based biotech startup Kineta today received a leg-up in its efforts to kill cancerous tumors using the immune system. Kineta announced an… Read More
Nine years after he underwent treatment for non-Hodgkin’s lymphoma, a potentially fatal but treatable form of cancer, Microsoft co-founder Paul… Read More
Two clinical studies have provided evidence suggesting that an experimental precision-medicine drug called larotrectinib can fight soft-tissue tumors regardless of… Read More
Seattle Genetics, a biotechnology company that develops antibody-based cancer treatments, announced Wednesday that it will acquire Cascadian Therapeutics and the… Read More
A study conducted by Fred Hutchinson Cancer Research Center, with contributions from researchers across North America, has found stark differences… Read More
